Athanassios Argiris
Athanassios Argiris
Verified email at
Cited by
Cited by
Head and neck cancer
A Argiris, MV Karamouzis, D Raben, RL Ferris
The Lancet 371 (9625), 1695-1709, 2008
Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non–small-cell lung cancer
SS Ramalingam, ML Maitland, P Frankel, AE Argiris, M Koczywas, ...
Journal of Clinical Oncology 28 (1), 56, 2010
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
HB Jie, PJ Schuler, SC Lee, RM Srivastava, A Argiris, S Ferrone, ...
Cancer research 75 (11), 2200-2210, 2015
Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review
BB Mittal, BR Pauloski, DJ Haraf, HJ Pelzer, A Argiris, EE Vokes, ...
International journal of radiation oncology, biology, physics 57 (5), 1219-1230, 2003
The impact of health insurance status on the survival of patients with head and neck cancer
J Kwok, SM Langevin, A Argiris, JR Grandis, WE Gooding, E Taioli
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy
A Argiris, BE Brockstein, DJ Haraf, KM Stenson, BB Mittal, MS Kies, ...
Clinical cancer research 10 (6), 1956-1962, 2004
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
A Argiris, M Ghebremichael, J Gilbert, JW Lee, K Sachidanandam, ...
Journal of Clinical Oncology 31 (11), 1405, 2013
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
SS Ramalingam, RA Parise, RK Ramananthan, TF Lagattuta, ...
Clinical cancer research 13 (12), 3605-3610, 2007
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
A Kotsakis, M Harasymczuk, B Schilling, V Georgoulias, A Argiris, ...
Journal of immunological methods 381 (1-2), 14-22, 2012
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
MV Karamouzis, JR Grandis, A Argiris
Jama 298 (1), 70-82, 2007
Prognostic factors and long‐term survivorship in patients with recurrent or metastatic carcinoma of the head and neck: An analysis of two Eastern Cooperative Oncology Group …
A Argiris, Y Li, A Forastiere
Cancer: Interdisciplinary International Journal of the American Cancer …, 2004
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
B Lacas, A Carmel, C Landais, SJ Wong, L Licitra, JS Tobias, B Burtness, ...
Radiotherapy and Oncology 156, 281-293, 2021
Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis: results from a northwestern university costs of cancer program pilot study …
NJ Nonzee, NA Dandade, T Markossian, M Agulnik, A Argiris, JD Patel, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2008
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial
DE Heron, RL Ferris, M Karamouzis, RS Andrade, EL Deeb, S Burton, ...
International Journal of Radiation Oncology* Biology* Physics 75 (5), 1493-1500, 2009
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer
MQ Baggstrom, Y Qi, M Koczywas, A Argiris, EA Johnson, MJ Millward, ...
Journal of Thoracic Oncology 6 (10), 1757-1760, 2011
Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer
A Argiris, KM Stenson, BE Brockstein, BB Mittal, H Pelzer, MS Kies, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2004
Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck
A Argiris, KJ Harrington, M Tahara, J Schulten, P Chomette, ...
Frontiers in oncology 7, 72, 2017
Phase I dendritic cell p53 peptide vaccine for head and neck cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo, S Trivedi, Y Lei, A Argiris, ...
Clinical Cancer Research 20 (9), 2433-2444, 2014
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and …
A Argiris, DE Heron, RP Smith, S Kim, MK Gibson, SY Lai, BF Branstetter, ...
Journal of clinical oncology 28 (36), 5294, 2010
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A Argiris, AP Kotsakis, T Hoang, FP Worden, P Savvides, MK Gibson, ...
Annals of oncology 24 (1), 220-225, 2013
The system can't perform the operation now. Try again later.
Articles 1–20